Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies

Annals of Neurology

Volumn 37, Issue 1 S, 1995, Pages 14-31

  van der Meche F G A ^a   van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BACTERIAL ANTIGEN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; AZATHIOPRINE; CORTICOSTEROID; GANGLIOSIDE ANTIBODY; IDIOTYPIC ANTIBODY; METHYLPREDNISOLONE;

ADULT; AGED; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; CAMPYLOBACTER; CHRONIC DISEASE; COMPARATIVE STUDY; DEMYELINATING DISEASE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGY; MIDDLE AGED; MOLECULAR MIMICRY; PHYSIOLOGY; PLASMAPHERESIS; POLYNEUROPATHY; POLYRADICULONEUROPATHY; REVIEW; CAMPYLOBACTER JEJUNI; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATING NEUROPATHY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; GUILLAIN BARRE SYNDROME; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; ANTIGENS, BACTERIAL; AUTOANTIGENS; AUTOIMMUNE DISEASES; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CELL ADHESION MOLECULES; CHRONIC DISEASE; DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; PLASMA EXCHANGE; POLYNEUROPATHIES; POLYRADICULONEUROPATHY; PREDNISONE;

EID: 0029050737     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410370704     Document Type: Article

References (167)

1. Criteria for diagnosis of Guillain‐Barré syndrome
2. Assessment of current diagnostic criteria for Guillain‐Barré syndrome
3. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)
4. Subacute idiopathic demyelinating polyradiculoneuropathy
5. Natural course of acute and chronic monophasic inflammatory demyelinating polyneuropathies (IDP)
6. Plasmapheresis and acute Guillain‐Barré syndrome
7. Upside down Guillain‐Barré syndrome. Abstract of the Dutch Neurological Society
8. Patterns of conduction failure in the Guillain‐Barré syndrome
9. An acute axonal form of Guillain‐Barré polyneuropathy
10. Kleyweg RP. Axonal damage in Guillain‐Barré syndrome
11. Axonal Guillain‐Barré
12. Is there an axonal variety of GBS?
13. The Guillain‐Barré syndrome
14. Acute polyradiculoneuritis: clinical analysis of 514 cases
15. Acute axonal neuropathy: a frequent cause of flaccid paralysis in China
16. Guillain‐Barré syndrome, a model for random conduction block
17. Conduction block denervation in Guillain‐Barré polyneuropathy
18. The Landry‐Guillain‐Barré syndrome: clinicopathologic report of fifty fatal cases and a critique of the literature
19. The inflammatory lesion in idiopathic polyneuritis
20. Pathology of the Guillain‐Barré syndrome
21. A clinicopathological study of the Guillain‐Barré syndrome
22. Interleukin‐6 levels in the cerebrospinal fluid and serum of patients with Guillain‐Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy
23. Detection of interleukin‐6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases
24. Clinical correlation with serum‐soluble interleukin‐2 receptor levels in Guillain‐Barré syndrome
25. T cell activation in Guillain‐Barré syndrome and in MS: elevated serum levels of soluble IL‐2 receptors
26. Serum interleukin‐2 concentrations in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis
27. Serum and CSF levels of soluble interleukin‐2 receptors in MS and other neurological diseases: a reappraisal
28. Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders
29. Tumor necrosis factor and interleukin‐1 in the CSF and sera of patients with multiple sclerosis
30. Thompson EJ. Elevated serum levels of tumor necrosis factor‐α in Guillain‐Barré syndrome
31. T lymphocyte activation antigens in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy
32. Immune reactions in the peripheral nervous system
33. Elevated neopterin levels in Guillain‐Barré syndrome. Further evidence of immune activation
34. Serum and CSF levels of soluble intercellular adhesion molecule‐1 (ICAM‐1) in inflammatory neurologic diseases
35. Anti‐peripheral nerve myelin antibodies in Guillain‐Barré syndrome bind a neutral glycolipid of peripheral myelin and cross‐react with Forssman antigen
36. Search for antibodies to neutral glycolipids in sera of patients with Guillain‐Barré syndrome
37. Guillain‐Barré syndrome: activated complement components C3a and C5a in CSF
38. Activation of terminal components of complement in patients with Guillain‐Barré syndrome and other demyelinating neuropathies
39. Passive transfer studies in Guillain‐Barré polyneuropathy
40. In vivo effects of sera from Guillain‐Barré subgroups: an electrophysiological and histological study on rat nerves
41. Speed BR
42. Dutch Guillain‐Barré Study group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain‐Barré syndrome
43. The clinical significance of biological prognostic factors including anti‐GM1 antibodies in Guillain‐Barré syndrome
44. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain‐Barré syndrome and in other neuroimmunological disorders
45. Guillain‐Barré syndrome associated with Campylobacter infection
46. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain‐Barré syndrome and controls: correlation and prognosis
47. Campylobacter jejuni strains from patients with Guillain‐Barré syndrome belong mostly to Penner serogroup 19 and contain β‐N‐acetylglucosamine residues
48. HLA‐B35 and acute axonal polyneuropathy following Campylobacter infection
49. A prospective study of acute idiopathic neuropathy. II. Antecedent events
50. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N‐acetylneuraminic acid and 2,3‐diamino‐2,3‐dideoxy‐D‐glucose
51. Localization of GM1 and Gal(ß1‐3)GalNAc antigenic determinants in peripheral nerve
52. A bacterium lipopolysaccharide that elicits Guillain‐Barré syndrome has a GM1 ganglioside‐like structure
53. Serum antibodies to gangliosides in Guillain‐Barré syndrome
54. Antibodies to gangliosides and myelin proteins in Guillain‐Barré syndrome
55. Antibody detection in Guillain‐Barré syndrome
56. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities and high titers of antiglycolipid antibodies
57. Multifocal motor neuropathy: response to human immune globulin
58. Antibodies to acidic glycolipids in Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy
59. Serum and CSF anti‐GM1 antibodies in patients with Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy
60. Acute axonal polyneuropathy associated with anti‐GM1 antibodies following Campylobacter enteritis
61. 1 antibodies
62. Acute motor neuropathy with antibodies to GM1 ganglioside
63. Guillain‐Barré syndrome associated with high titers of anti‐GM1 antibodies
64. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain‐Barré syndrome
65. Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside
66. Acute relapsing sensory neuropathy associated with IgM antibody against B‐series gangliosides containing a GalNAcß1‐4(Gal3‐2αNeuAc8‐2αNeuAc)ß1 configuration
67. Localization of GM1 and GD1b antigens in the human peripheral nervous system
68. Anti‐GM1 IgA antibodies in Guillain‐Barré syndrome
69. Anti‐B‐series gangliosiderecognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons
70. 1b is a possible marker of Miller Fisher syndrome
71. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside
72. Frequent presence of anti‐GQ1b antibody in Fisher's syndrome
73. Serum factor in Miller‐Fisher variant of Guillain‐Barré syndrome and neurotransmitter release
74. 1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome
75. Plasmapheresis and Guillain‐Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis
76. Controlled trial of prednisolone in acute polyneuropathy
77. Efficiency of plasma exchange in Guillain‐Barré syndrome: role of replacement fluids
78. Plasma exchange morbidity in Guillain‐Barré syndrome: results from the French prospective, double‐blind, randomized, multicenter study
79. Manipulating the immune system with immuneglobulin
80. Plasma and gamma‐globulin infusion in chronic inflammatory polyneuropathy
81. Treatment of Guillain‐Barré syndrome with high dose gammaglobulin
82. Sample size requirements for evaluating a conservative therapy
83. The Guillain‐Barré syndrome
84. A prospective study of acute idiopathic neuropathy. 1. Clinical features and their prognostic value
85. Détermination du nombre optimal d'échanges plasmatiques dans le syndrome de Guillain‐Barré selon la gravité. Résultats d'une étude multicentrique randomisée. Société de Réanimation de Langue Française, Paris,20–22 Janvier 1994
86. Plasmapheresis in children with Guillain‐Barré syndrome
87. Intravenous gammaglobulin (IVGG) therapy in children with severe acute inflammatory demyelinating polyneuropathy (AIDP)
88. Intravenous immune globulin is also an efficient therapy of acute Guillain‐Barré syndrome in afflicted children
89. Treatment of Fisher's variant of Guillain‐Barré syndrome by exchange transfusion
90. High dose immunoglobulin therapy is effective in the Miller Fisher syndrome
91. The use of intravenous immunoglobulin in Miller Fisher syndrome
92. Plasmapheresis in the treatment of Guillain‐Barré syndrome: a cost‐effective analysis
93. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement
94. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome
95. Treatment related fluctuations in Guillain‐Barré syndrome after high‐dose immunoglobulins or plasma exchange
96. Human immune globulin infusion in Guillain‐Barré syndrome: worsening during and after treatment
97. Relapse in Guillain‐Barré syndrome after treatment with human immune globulin
98. High‐dose intravenous immunoglobulin in the treatment of Guillain‐Barré syndrome: a preliminary open study
99. Treatment of Guillain‐Barré syndrome with high‐dose intravenous immunoglobulins–a comparison with plasma exchange
100. Intravenous immunoglobulin versus plasma exchange in Guillain‐Barré syndrome
101. Guillain‐Barré Syndrome Steroid Trial group. Double‐blind trial of intravenous methylprednisolone in Guillain‐Barré syndrome
102. Combination of steroids and immunoglobulin in chronic refractory idiopathic thrombocytopenic purpura (ITP) enabling renal stone fragmentation by lithotripsy
103. Dutch Guillain‐Barré Study group. Treatment of Guillain‐Barré syndrome with high‐dose immune globulins combined with methylprednisolone: a pilot study
104. Chronic inflammatory demyelinating polyneuropathy
105. Chronic inflammatory polyradiculoneuropathy
106. Chronic inflammatory demyelinating polyradiculoneuropathy, clinical characteristics, course and recommendations for diagnostic criteria
107. Inflammatory neuropathy: pathogenesis and clinical features
108. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases
109. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
110. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
111. IgG monoclonal paraproteinaemia and peripheral neuropathy
112. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance
113. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG andIgA paraproteinaemia
114. Plasmapheresis in chronic demyelinating polyneuropathy
115. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy
116. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy
117. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM‐MGUS neuropathies are different than IgG‐MGUS
118. Delayed appearance of anti‐myelin‐associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy
119. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with IgM monoclonal gammopathy of unknown significance
120. Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin
121. Polyradiculonevrites chroniques
122. Chronic relapsing polyneuritis
123. Macrophage responses in inflammatory demyelinating neuropathies
124. Immunoglobulin and complement deposits in peripheral nerves of patients with chronic relapsing polyneuropathy
125. Immunocytochemical studies of serum proteins and immunoglobulins in human sural nerve biopsies
126. Localization of Fc‐y receptors and complement receptors on human peripheral nerve fibres by immunoelectron microscopy
127. Experimental allergic neuritis induced by sensitization with galactocerebroside
128. Relation of clinical, serological, morphological, and electrophysiological findings in galactocerebroside‐induced experimental allergic neuritis
129. Antiserum‐mediated demyelination: relationship between remyelination and functional recovery
130. Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2‐protein reactive T cell lines
131. Experimental allergic neuritis: effect of plasma infusions
132. Regulation of auto‐antibodies in inflammatory demyelinating polyneuropathy: spontaneous and therapeutic
133. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin
134. Antibodies to sulfated glycolipids in Guillain‐Barré syndrome
135. High‐titer selective serum anti‐beta tubulin antibodies in chronic inflammatory demyelinating polyneuropathy
136. T cell responses to myelin proteins in Guillain‐Barré syndrome
137. HLA antigens in the Landry‐Guillain‐Barré syndrome and chronic relapsing polyneuritis
138. HLA antigens in chronic relapsing idiopathic inflammatory polyneuropathy
139. HLA antigens in chronic inflammatory demyelinating polyneuropathy
140. HLA antigens in patients with chronic inflammatory demyelinating polyneuropathy
141. Recurrent polyneuropathies and their corticosteroid treatment. With five‐year observations of aplacebocontrolled case treated with corticotrophin, cortisone, and prednisone
142. Remarkable recovery of a steroidresponsive recurrent polyneuropathy
143. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy
144. Cyclosporin A in the treatment of chronic demyelinating polyneuropathy
145. High‐dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy
146. High‐dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy
147. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood. Treatment with high‐dose intravenous immunoglobulin
148. Strengers PFW, et al. High‐dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double‐blind placebocontrolled crossover study
149. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study
150. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
151. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease
152. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of Kawasaki syndrome
153. Effect of high‐dose intravenous immunoglobulin therapy on blood rheology
154. High‐dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events
155. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis
156. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases
157. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases
158. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IgIV
159. Intravenous immunoglobulin treatment of experimental T‐cell mediated autoimmune disease: up‐regulation of T cell proliferation and down‐regulation of TNFα secretion
160. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro
161. Anti‐neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin
162. On the mechanism of high‐dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy
163. Spontaneous recovery from the Guillain‐Barré syndrome is associated with anti‐idiotypic antibodies recognizing a cross‐reactive idiotype on anti‐neuroblastoma cell line antibodies